Efficacy and safety of rozanolixizumab in patients with muscle-specific tyrosine kinase autoantibody-positive generalised myasthenia gravis: a subgroup analysis of the randomised, double-blind, placebo-controlled, adaptive phase III MycarinG study.
Thomas H BrannaganSabrina SacconiGiovanni AntoniniElena Cortés-VicenteJulian GrosskreutzZabeen K MahuwalaRenato MantegazzaRobert M PascuzziKimiaki UtsugisawaJohn VissingTuan VuHeinz WiendlMarion BoehnleinBernhard GreveFranz WolteringVera BrilPublished in: Therapeutic advances in neurological disorders (2024)
ClinicalTrials.gov: NCT03971422 (https://clinicaltrials.gov/study/NCT03971422); EU Clinical Trials Register: EudraCT 2019-000968-18 (https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000968-18/GB).